Tests a urea toe nail patch in adults with fragile, fungal or psoriatic nails
Tests a urea nail patch against a placebo patch in adults with toenail problems.
Plain-language title generated from the registry record
Registry title: Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis
Key facts
- Where
- Milan, ItalySee the site
- Phase
- Phase 3
Where in Italy
- Clinica Dermatologica - Policlinico - Università degli Studi di Milano Via Francesco Sforza- MilanoMilan, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Wooshin Labottach Co., Ltd.
- Trial code
- NCT07029516
- Record updated
- 26 January 2026
- Original description
A randomized, double blind, placebo-controlled, unicenter, parallel group study to assess the efficacy, safety and tolerability of a multi-funtion toe nail patch in patients affected by nail fragility, nail mychosis and psoriasis 72 patients in 6 subgroups Treatment duration 3 months + 1 month follow-upRead full original descriptionShow less
A Randomized, Double Blind, Placebo-controlled, Unicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of a Multi-funtion Toe Nail Patch in Patients Affected by Nail Fragility, Nail Mychosis and Psoriasis
A randomized, double blind, placebo-controlled, unicenter, parallel group study to assess the efficacy, safety and tolerability of a multi-funtion toe nail patch in patients affected by nail fragility, nail mychosis and psoriasis 72 patients in 6 subgroups Treatment duration 3 months + 1 month follow-up
Inclusion: aged 18 years or older Fragility Nails Distal Subungual Onychomycosis Nail Psoriasis affecting ≤75% of the nail bed according to a photographic documentation and to a subjective evaluation by the Investigator.
Exclusion: Patients who have participated in another clinical nail study during the previous three months; Patients with conditions known to cause abnormal nail appearance, immunosuppression and signs of severe peripheral circulatory insufficiency; Patients who have a known allergy to any of the study treatments; Patients with unrelated nail disorders: onychomycosis, nail psoriasis, genetically induced onychodystrophy; Patients with other nail disorders, active or severe psoriasis elsewhere, other autoimmune or inflammatory diseases; Patients that have proximal subungual onychomycosis, if their distal subungual onychomycosis is extended into the proximal portion of the nail or if it affects >75% of the nail; Patients who had used topical antifungal, anti-psoriasis nail treatment within one month or systemic antifungal treatment within three months.